"Thienamycins"[nm] - Search Results

Year	Number of Results
1957	1
1960	1
1977	1
1978	1
1979	3
1980	15
1981	15
1982	34
1983	48
1984	63
1985	114
1986	181
1987	102
1988	59
1989	45
1990	15
1991	25
1992	72
1993	32
1994	50
1995	105
1996	98
1997	124
1998	131
1999	98
2000	104
2001	87
2002	74
2003	68
2004	86
2005	93
2006	100
2007	100
2008	118
2009	91
2010	122
2011	181
2012	159
2013	140
2014	171
2015	200
2016	212
2017	230
2018	76
2019	9
2020	11
2021	8
2022	11
2023	4
2024	4

1

[The overlap Stevens-Johnson syndrome due to meropenem administration. Clinical case and nursing care].

Rossi E. Rossi E. Assist Inferm Ric. 2024 Apr-Jun;43(2):83-90. doi: 10.1702/4280.42614. Assist Inferm Ric. 2024. PMID: 38873717 Italian.

2

In vitro activity, pharmacodynamic profile and dose optimization of biapenem against NDM and OXA-48-like carbapenemase-producing Klebsiella pneumoniae: A multicentre study in Thailand.

Nasomsong W, Siangtrong C, Nulsopapon P, Pungcharoenkijkul S, Boonmee P, Santimaleeworagun W. Nasomsong W, et al. J Glob Antimicrob Resist. 2024 Jun;37:219-224. doi: 10.1016/j.jgar.2024.03.010. Epub 2024 Mar 27. J Glob Antimicrob Resist. 2024. PMID: 38552877 Free article.

3

Win Ratio Analyses of Piperacillin-Tazobactam Versus Meropenem for Ceftriaxone-Nonsusceptible Escherichia coli or Klebsiella pneumoniae Bloodstream Infections: Post Hoc Insights From the MERINO Trial.

Hardy M, Harris PNA, Paterson DL, Chatfield MD, Mo Y; MERINO Trial Investigators. Hardy M, et al. Clin Infect Dis. 2024 Jun 14;78(6):1482-1489. doi: 10.1093/cid/ciae050. Clin Infect Dis. 2024. PMID: 38306577 Clinical Trial.

4

Evaluation of antimicrobial susceptibility tests for Acinetobacter and Pseudomonas species using disks containing a high dose of meropenem.

Endo S, Tada T, Oshiro S, Hishinuma T, Tohya M, Watanabe S, Sekiguchi JI, Abe M, Nakada K, Kirikae T. Endo S, et al. Sci Rep. 2024 Feb 2;14(1):2749. doi: 10.1038/s41598-024-52538-x. Sci Rep. 2024. PMID: 38302510 Free PMC article.

5

Investigation of in vitro antimicrobial and cytotoxic effects of gold nanoparticles capped with meropenem and imipenem.

Ciftci N, Sargin I, Arslan G, Karakurt S, Arslan U. Ciftci N, et al. Nanomedicine (Lond). 2023 Oct;18(24):1719-1731. doi: 10.2217/nnm-2023-0223. Epub 2023 Nov 15. Nanomedicine (Lond). 2023. PMID: 37965902

6

Pharmacokinetics and Therapeutic Target Attainment of Meropenem in Pediatric Post-Liver Transplant Patients: Extended vs Intermittent Infusion.

Morales Junior R, Juodinis VD, Telles JP, Romano P, Duarte NJC, De Souza DC, Santos SRCJ. Morales Junior R, et al. Transplant Proc. 2023 Dec;55(10):2456-2461. doi: 10.1016/j.transproceed.2023.09.020. Epub 2023 Nov 2. Transplant Proc. 2023. PMID: 37923571

7

Evaluation of the meropenem dosage and administration schedule in patients with bacteremia initial therapy.

Tai T, Yamamoto T, Yamaguchi K, Watanabe M, Tanaka H, Muraki Y, Kosaka S. Tai T, et al. J Infect Chemother. 2023 Aug;29(8):749-753. doi: 10.1016/j.jiac.2023.04.004. Epub 2023 Apr 20. J Infect Chemother. 2023. PMID: 37086895

8

Population Pharmacokinetic Model and Dosing Simulation of Meropenem Using Measured Creatinine Clearance for Patients with Sepsis.

Fukumoto S, Ohbayashi M, Okada A, Kohyama N, Tamatsukuri T, Inoue H, Kato A, Kotani T, Sagara H, Dohi K, Kogo M. Fukumoto S, et al. Ther Drug Monit. 2023 Jun 1;45(3):392-399. doi: 10.1097/FTD.0000000000001040. Epub 2023 May 8. Ther Drug Monit. 2023. PMID: 36253888 Free PMC article.

9

Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study.

Kumta N, Heffernan AJ, Cotta MO, Wallis SC, Livermore A, Starr T, Wong WT, Joynt GM, Lipman J, Roberts JA. Kumta N, et al. Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0014222. doi: 10.1128/aac.00142-22. Epub 2022 Jul 6. Antimicrob Agents Chemother. 2022. PMID: 35862757 Free PMC article.

10

Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue.

Alshaer MH, Barlow B, Maranchick N, Moser M, Gramss L, Burgmann H, Jalali VA, Wölfl-Duchek M, Jäger W, Poschner S, Plöchl W, Reinprecht A, Rössler K, Gruber A, Zeitlinger M, Peloquin CA, Hosmann A. Alshaer MH, et al. Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0043822. doi: 10.1128/aac.00438-22. Epub 2022 Jul 14. Antimicrob Agents Chemother. 2022. PMID: 35862739 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

3,622 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

3,622 results

Results by year